Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: J Immunol. 2011 Aug 31;187(7):3704–3711. doi: 10.4049/jimmunol.1101823

FIGURE 1.

FIGURE 1

Therapeutic efficacy of Ab 4K8 against disease caused by the 1918 A (H1N1) virus in mice. Mice were inoculated on day 0 and treated on day 1 with the indicated antibody and dose. In each group, six mice were monitored every other day for survival (A) and weight (B). At all dose levels, the differences in survival distribution between the 4K8 and the human IgG control groups were significant by log-rank test (p = 0.001 for the high-dose level, p < 0.001 for the medium-dose level, p < 0.01 for the low-dose level).